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ABSTRACT
High-dose melphalan has been commonly used as conditioning for amyloidosis with considerable toxicity. We
hypothesized that the novel conditioning regimen of 550 cGy total body irradiation (TBI) alone for autologous
peripheral blood stem cell transplantation would have reduced organ toxicity and thus permit safer transplan-
tation of primary amyloidosis patients, even those with poor risk disease. The comprehensive regimen included
pretransplantation chemotherapy, single-dose TBI alone (550 cGy at 30 cGy/min) conditioning, and post-
transplantation interferon-alpha maintenance. Thirteen patients were enrolled in this feasibility study. Pa-
tients with multiorgan involvement were included; 10 patients had poor or intermediate risk disease. Cardiac
toxicity was significant. Treatment-related mortality through 100 days post-transplantation was 15% and was
caused by cardiac mortality. One patient died from arrhythmia after receiving TBI; 2 patients had grade IV
cardiac toxicity (with subsequent complete recovery). One patient died 1 month after mobilization from
progressive cardiomyopathy and never received conditioning. However, noncardiac organ toxicity was mild. No
patient required parenteral nutrition support; no patient developed mucositis; and no patient experienced
gastrointestinal bleeding following transplantation. The complete hematologic remission rate was 45%, with
pretransplantation chemotherapy being the most active part of the regimen. Survival estimates from enrollment to
1 and 2 years post-transplantation were 66% and 47%, respectively. Causes of death were disease progression (6),
myelodysplasia (1), arrhythmia following TBI (1), and congestive heart failure after mobilization (1). In this cohort
of primary amyloidosis patients, the transplantation regimen of 550 cGy TBI was feasible and associated with
modest treatment-related mortality. Efficacy with TBI conditioning may be reduced compared with high-dose
melphalan, but this should be explored in a future trial with a larger cohort of patients.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Primary systemic (AL) amyloidosis is a plasma cell
disorder related to myeloma. Symptoms are caused by
the deposition of monoclonal immunoglobulin or im-
munoglobulin light-chain fragments into organ tis-
sues. Organs commonly affected by amyloid deposi-
tion include the kidneys, liver, heart, skin/soft tissue,
gastrointestinal tract, peripheral nervous system, and
bone marrow. Unfortunately, AL amyloidosis typi-
cally responds poorly to chemotherapy, with median
overall survival of 18 months [1]. Since the mid-1990s,
attempts to improve response rates and survival have
included the use of colchicine [1], high-dose dexa-
methasone [2], and autologous transplantation. For
the related disorder myeloma, autologous transplan-
tation has become the standard of care for younger
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patients (age 65 years) [3]. Given the similarities
between myeloma and AL amyloidosis, transplanta-
tion may be effective in amyloidosis as well, and sev-
eral centers have used high-dose melphalan as condi-
tioning for both disorders. However, recent studies
indicated that AL amyloidosis patients receiving au-
tologous transplantation experienced substantially
higher mortality from regimen-related toxicities com-
pared with myeloma patients, especially cardiac mor-
tality. Autologous transplantation studies in AL amy-
loidosis have reported 100-day mortality rates of 15%
to 43% [4-9], a result much higher than the expected
treatment-related mortality (TRM) of less than 5%
seen in myeloma [3,10]. Given this high TRM, many
studies using autologous transplantation for AL amy-
loidosis have limited the entry criteria to exclude pa-
tients with signiﬁcant organ dysfunction.
Alternatively, use of a less toxic regimen may allow
transplantation of poor-risk AL amyloidosis patients
who do not meet standard inclusion criteria and who
would otherwise not be candidates for transplantation.
This study was undertaken with the hypothesis that
the conditioning regimen of single-dose total body
irradiation (TBI) alone (550 cGy in 1 dose at a dose
rate of 30 cGy/min) would be feasible for AL amy-
loidosis patients, including poor-risk patients (risk was
determined according to guidelines proposed by
Comenzo and Gertz) [11]. Previously, we reported
favorable results using a similar schedule of single-
dose TBI (plus cyclophosphamide) as conditioning for
allogeneic transplantation. We showed that allogeneic
transplantation patients conditioned in this manner
had low TRM (7% to 19%, depending on disease
type) and low fatal regimen-related organ toxicity
(2.5%) [12]. This encouraging experience was the ba-
sis for exploring the feasibility of single-dose TBI
alone as conditioning for autologous peripheral blood
stem cell (PBSC) transplantation in AL amyloidosis.
Using a comprehensive approach modeled after that
used for the treatment of myeloma [10], we adminis-
tered pretransplantation chemotherapy, single-dose
TBI alone as conditioning for autologous PSBC trans-
plantation, and post-transplantation maintenance in-
terferon (IFN) to AL amyloidosis patients. In this
report, we describe the tolerability, toxicity, and efﬁ-
cacy of the regimen for 13 patients treated according
to this plan.
MATERIALS AND METHODS
Eligibility and Disease Evaluation
Inclusion criteria included diagnosis of AL amy-
loidosis, Eastern Cooperative Oncology Group per-
formance status performance status 3, and signed
informed consent. Diagnosis was established on the
basis of biopsy-proven amyloidosis in association with
a clonal plasma cell disorder detected by electrophore-
sis/immunoﬁxation of serum/urine or by immunohis-
tochemical staining of amyloid-involved tissue biopsy
material. There was one exception to this diagnostic
criteria: unique patient number (UPN) 1 was included
in the study on the basis of multi-organ amyloid in-
volvement when secondary causes of amyloidosis were
excluded. For this trial, exclusion criteria were age
18 years, active infection, or human immunodeﬁ-
ciency virus positive. Patients with disease causing
only carpal tunnel syndrome were excluded given
their favorable prognosis. Patients who had previously
received treatment including chemotherapy were not
excluded. Patients were not excluded on the basis of
elevated creatinine or reduced cardiac function. How-
ever, 1 patient was removed from study following an
inadequate PBSC collection after the patient subse-
quently developed progressive congestive heart failure
from amyloid cardiomyopathy requiring continuous
inotropes. For patients who had failed chemotherapy
before enrollment, alternate pretransplantation che-
motherapy was given. The Institutional Review Board
approved the protocol and consent forms. Based on
referral patterns to this institution, consent to partic-
ipate occurred at any time point between initial diag-
nosis and completion of pretransplantation chemo-
therapy, but it was always obtained before collection
of autologous PBSC. Disease evaluations were per-
formed before beginning chemotherapy, immediately
pretransplantation, day 100 post-transplantation, year
1, and yearly thereafter. Evaluations included a history
and physical examination, bone marrow biopsy and
aspiration, serum/urine electrophoresis and immuno-
ﬁxation studies, 24-hour urine collection for protein,
liver function testing, and assessment of cardiac func-
tion with echocardiography/nuclear ventriculography.
Additional pretransplantation tests consisted of com-
plete blood count, chemistry panel, assessment of pul-
monary function, chest x-ray, and electrocardiogram.
Study Design
Four to 6 cycles of pretransplantation chemother-
apy were planned. Dexamethasone alone was recom-
mended (40 mg orally daily on days 1-4, 9-12, and
17-20; repeated every 28 days), but other regimens
were permitted including melphalan/prednisone
(MP), vincristine/adriamycin/dexamethasone (VAD),
and vincristine/melphalan/cyclophosphamide/pred-
nisone (VMCP). Patients with no signiﬁcant response
to previous therapy were treated with one of the other
listed regimens on referral to our center. Data was
retrospectively collected for patients who had received
therapy before enrollment and then prospectively col-
lected once treated at our center.
Following completion of chemotherapy, mobiliza-
tion of autologous PBSC was performed with granu-
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locyte colony-stimulating factor at 10 g/kg/day to
achieve a target collection of 2.5 million CD34 cells/
kg. Autologous PBSC were cryopreserved using stan-
dard techniques. Total body irradiation was adminis-
tered in 1 dose of 550 cGy at a dose rate of 30
cGy/min. The TBI was delivered in parallel-opposed
lateral ﬁelds with 6 mV photons using a Clinac 600
CD (Varian Medical Systems, Alpharetta, GA). Pa-
tients were treated in a sitting position with a 300-cm
distance from source to midline. The point of dose
prescription was a single point, midline in the body, at
the level of the umbilicus. A large Lucite plate was
placed near the patient to enhance the skin dose, and
a tissue compensator was used to keep the midline
dose to the head and neck within 110% of the pre-
scription dose. Ion chamber and diode placed on dif-
ferent parts of the body were used to ensure that the
measured and calculated doses were within acceptable
limits. Autologous PBSC were infused on the same
day as the administration of TBI, but no earlier than 4
hours after TBI. After recovery from transplantation
toxicities and with sustained platelet count 75,000/
L, patients were given IFN-alpha at a dose of 3
mU/m2 subcutaneously 3 times a week for 1 year
post-transplantation.
Response Criteria
Organ response criteria were similar to those used
in previous trials [5]. Amyloid-related organ function
was assessed with speciﬁc response criteria for 3 or-
gans: the kidneys, the liver, and the heart. For the
kidney, response was a 50% decrease in 24-hour urine
total protein excretion in the absence of an increase in
serum creatinine. For the liver, response was a 50%
reduction in serum alkaline phosphatase with no in-
crease in transaminases, bilirubin, or liver size. For the
heart, response was a 20% improvement in ejection
fraction. Hematologic response assessments con-
formed to those established for multiple myeloma [13]
and used in previous AL amyloidosis transplantation
trials [5]. Complete hematologic response (CHR) re-
quired complete resolution of any serum/urine mono-
clonal protein, including resolution of light chains
noted on urine immunoﬁxation and less than 5%
marrow plasma cells (with polytypic light chain ex-
pression). Complete eradication of urinary light
chains on immunoﬁxation was required if this was the
only criterion for evaluation. Partial hematologic re-
sponse (PHR) required a 50% reduction in monoclo-
nal protein in serum or urine.
Safety Monitoring/ Statistical Analysis
This study was performed to assess the feasibility
of low-dose (550 cGy) conditioning for AL amyloid-
osis patients, and plans were made to close the study if
2 out of the ﬁrst 5 patients who underwent transplan-
tation died of TRM within the ﬁrst 100 days post-
transplantation. Because there were no early deaths in
the ﬁrst 5 patients, 13 patients were enrolled to con-
ﬁrm the feasibility of this approach. Toxicity was as-
sessed using the National Cancer Institute Cancer
Therapy Evaluation Program v2.0 guidelines. De-
scriptive statistics were used to analyze and present
data. Overall survival was calculated from the time of
enrollment using the Kaplan-Meier method [14].
RESULTS
Patient Characteristics
From 1997 to 2001, our group saw 19 patients
with AL amyloidosis; 13 were enrolled on this proto-
col. Six patients were not enrolled because of patient
wishes (2), physician decision based on low diffusion
capacity of carbon monoxide (1), age (1), or unknown
reasons (2). The study population had a median age of
56 years (range, 35 to 67 years) with 10 of 13 patients
older than age 50. Median interval from diagnosis to
transplantation was 9 months (range, 4 to 30). Because
enrollment was permitted at any point between initial
referral and stem cell mobilization, the time between
enrollment and transplantation varied with a range of
0 to 4 months. Twelve patients had at least 2 organs
involved by amyloid, and 5 patients had 3 or more.
Recently proposed risk-stratiﬁcation guidelines [11]
would characterize most of these patients as either
poor (5) or intermediate risk (5). The predominant
amyloid-affected organ for each patient was liver (5),
heart (3), kidney (2), soft tissue (2), and autonomic
nervous system (1). Major organ involvement among
all patients included kidney (7 patients), liver (7), heart
(7), and gastrointestinal tract (3). Ten patients had
detectable monoclonal protein: 9 in the serum and 6
in the urine. Two patients had only a plasma cell clone
detected in the marrow. Three patients presented with
serum creatinine2.0 (one on dialysis), and 2 had low
left ventricular ejection fractions of 25% to 40%.
Another patient had a history of cardiac arrhythmias.
Five patients had nephrotic range proteinuria before
receiving pretransplantation chemotherapy. Table 1
summarizes the patient characteristics.
Pretransplantation Chemotherapy
Patients received the following chemotherapy reg-
imens before transplantation: dexamethasone (4 pa-
tients), melphalan or MP (7), VAD (4), and VMCP
(1). One patient received MP with poor response and
was subsequently treated with VAD before referral to
our center. One patient received VAD followed by
high-dose melphalan for multiple myeloma 2 years
and did not receive subsequent pretransplantation
chemotherapy before referral to our center. Another
patient was initially treated initially with dexametha-
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Table 1. Patient Characteristics
UPN Age/Sex Risk Group*
Amyloid Involvement Measurable
Hematologic
Criteria
Previous
Chemo/Study
Chemo†
Chemotherapy Response TBI Response
OutcomePredominant Other Organ Heme Organ‡ Heme Organ‡
1 58M Poor Liver GI, kidney,
heart
Not evaluable(NE) None/MP NE NE NE Liver-NR Alk
phos 169 to
172
Died of progression
day 375
2 56F Poor Liver GI,
lymphatic,
heart, liver
Serum M  4.5
Marrow 20%
plasma cells-
lambda L.C.
None/VMCP PHR Liver-NR (No
response)
Still PHR
Serum M 
0.8
Liver-NR Alk
phos 176 to
288
Died of progression
day 1024
3 67M Poor Liver Autonomic
nervous,
kidney
Serum M  0.5,
Urine lambda
L.C.
None/MP CHR Kidney-Yes(Y)
24hr UTP
down (12g to
2.9g/24hr)
Liver-NR
NE (in CHR) Kidney-Y 24hr
UTP down to
1.2g Liver-Y
Alk phos 304
to 103
Died of AL
progression with
MDS/AML day
781
4 56M Intermediate Heart Kidney Serum M  1.2
Urine M  1.9
Urine kappa L.C.
None/DEX PHR Heart-NR Kidney-
NR
Converted to
CHR
Heart-NR
Kidney-NR
Died of progression
day 577
5 63F Good Soft tissue Adenopathy 29% marrow plasma
cells urine kappa
L.C.
None/VAD PHR NE Converted to
CHR
NE Alive and in remission
day 720
6 35F Good Soft tissue Liver Serum M  0.4 VAD then HD
Melphalan/
None
None NE M  0.4 NE Died of progression
day 220
7 53M Good Autonomic
nervous
system
Carpal
tunnel
Serum M  0.3 None/VAD None NE M  0.4 NE Alive without
progression day
730
8 48M Intermediate Liver Kidney NE Amyloid biopsy
material positive
for lambda L.C.
None/DEX NE Kidney-NR Liver-
NR
NE Kidney-Y 24hr
UTP down
(17g to 4.7g/
24hr) Liver-Y
Alk phos 820
to 204
Myocardial infarction
after TBI; alive
without
progression day 
598
9 48M Intermediate Kidney Heart Serum kappa L.C. MP/VAD CHR Kidney-Y 24hr
UTP down (16g
to 5g/24hr)
NE (in CHR) Kidney-Y 24hr
UTP down to
1.1g
Died of pneumonia
and MDS day 332,
(AL in remission)
10 52F Poor Heart GI, kidney,
soft tissue,
autonomic
nervous
system
Serum and urine
lambda L.C.
Marrow flow 
None/MP None Heart-NR Kidney-
NR
None Heart-NR-
progression
Kidney-Y 24
hr UTP down
(2.5 to 0.9g/
24hr)
Atrial arrhythmia and
hypotension with
PBSC infusion;
Died of progression
day 151
11 58F Intermediate Kidney Serum M  1.2
Urine lambda
L.C.
None/DEX
and MP
CHR Kidney-Y 24hr
UTP down (5g
to 2.4g/24hr)
NE (in CHR) Kidney-Y 24hr
UTP down to
0.9g
Alive in remission day
266
12 59M Poor Heart Liver, soft
tissue
Marrow flow 
lambda L.C.
MP/None None Heart-NR-
progression
Liver-NR
NE (death) NE Died before PBSC
re-collection due to
AL-cardiomyopathy
13 54M Intermediate Liver Heart (post-
mortem)
Serum kappa, urine
lambda L.C.
None/DEX None Liver-NR-
progression
NE (death) NE Died: arrhythmia
after TBI on day 0;
autopsy:  cardiac
amyloid
*According to proposed guidelines.11
†Previous chemo refers to treatment given before referral to our center (with retrospective data analysis; study chemo refers to treatment given after or concurrently with referral to our center (with prospective
data analysis).
‡Listings limited to evaluable dysfunction of kidneys, liver, or heart as assessed by: 24hr urinary protein, liver testing (Alk phos), and cardiac ejection fraction. Units expressed as follows: alkaline phosphatase,
u/L; serum M spike, g/dL; urine M spike, g/d; serum Cr, mg/dL; bilirubin, mg/dL; 24hr UTP, 24 hour urine total protein.
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sone and subsequently with MP because of steroid-
induced psychosis. Additional complications from
chemotherapy included leucopenia, thrombocytope-
nia, hyperglycemia, and mucositis. One patient with a
pre-existing coagulopathy had gastrointestinal bleed-
ing after receiving MP. Estimated melphalan doses for
patients who received MP (n  6) ranged from 400 to
800 mg (median, 465 mg). Two patients developed
myelodysplasia or acute myelogenous leukemia after
the transplantation; these 2 had cumulatively received
400 mg and 840 mg of melphalan, respectively, before
mobilization. Responses to pretransplantation chemo-
therapy are summarized in Table 1 and are reviewed
later in this report.
Mobilization of Stem Cells
Following completion of pretransplantation che-
motherapy, granulocyte colony-stimulating factor
mobilized PBSC were collected. For patients who
received conditioning (n 12), the median number of
collections required was 2 (range, 1 to 12). One other
patient had a poor collection, and no further attempt
was made at collection because the patient developed
worsening heart failure. He was removed from study
because of the requirement for continuous inotrope
support and died 1 month after the initial suboptimal
mobilization. Four patients required more than 3
apheresis collections; all had previously received MP
(as did the patient who was removed from study before
a second collection.) Median cell dose (n  12) was
2.93  106 CD34 cells/kg (range, 2.0 to 7.7). As
noted above, 2 patients developed MDS/AML post-
transplantation, and both required more than 1
apheresis (2 collections and 3 collections). One patient
developed progressive amyloid cardiomyopathy fol-
lowing mobilization as described, but no serious car-
diac complications were noted in the other 12 patients
during the mobilization and collection period.
Conditioning and Transplantation
Twelve patients received the conditioning regi-
men as planned. Cardiac toxicity, occurring in 3 pa-
tients, was the most signiﬁcant problem experienced
following TBI or during infusion of stem cells. Fatal
cardiac toxicity occurred in 1 patient following the
administration of TBI (before PBSC infusion). After
initially experiencing chest pain with marked ST-seg-
ment depression on electrocardiogram, the patient
subsequently developed refractory bradycardia and
died. At autopsy, the cause of death was determined to
be diffuse cardiac amyloidosis. Another patient suf-
fered a myocardial infarction following TBI. On car-
diac catheterization, this patient was found to have
coronary artery disease and required placement of a
coronary stent. A third patient, who had a pretrans-
plantation history of amyloid-related atrial arrhyth-
mias, experienced atrial ﬂutter/ﬁbrillation, heart fail-
ure, and hypotension during the infusion of stem cells
and required vasopressors for approximately 24 hours
before recovery.
Conversely, noncardiac organ toxicity following
conditioning was mild. Gastrointestinal toxicity was
minimal, as mucositis was not observed. Parenteral
nutritional support was not required, and gastrointes-
tinal bleeding did not occur. One patient was treated
with steroids for radiation pneumonitis (grade 2 tox-
icity) within the ﬁrst 30 days post-transplantation and
had subsequent complete recovery. Adverse events are
summarized in Table 2. Two patients experienced
grade 4 toxicity because of infection. One of these
patients died of pneumonia on post-transplantation
day 332 with amyloidosis in remission. The other
was noted to have fungal sinusitis before his death
from disease progression on post-transplantation day
375. Both of these patients had also experienced
prolonged neutropenia following transplantation.
Neutropenia (absolute neutrophoil count [ANC]
500/L) was observed in only 5 of 11 evaluable
Table 2. Adverse Events Following TBI and Autologous
Transplantation
Toxicity
No. of Patients with Toxicity
(Grade*)
1 2 3 4
Neutropenia 2 4 2
Thrombocytopenia 2 3 1 4
Infection 1 6 2
Hemorrhage 1 2
Transfusion
reaction 1
Stem cell infusion
reaction 1
Thrombosis 1
Mucositis
Pneumonitis 1
Esophagitis 1
Nausea/vomiting 1 1
Increased LFT 4 1
Hypotension 1 1
Hypertension 2
Arrhythmia 2
MI 1
Dyspnea 3 1
CHF 1
Second malignancy 2
Rash 4 1
Hypothyroid 1
Hypercalcemia 1
Pain 1 1
Anxiety 3
Depression 3
Constitutional
(including fever,
fatigue, non-CHF
edema, insomnia) 6 7
*NCI-CTEP v2.0.
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patients. In 3 of these 5 patients, the number of days
with ANC500/L was only 3, 1, and 1, respectively.
Two patients experienced longer neutropenic periods.
One of these, previously treated with melphalan and
prednisone, had ANC500/L for 9 days. The other
patient with prolonged neutropenia had also been
treated extensively with melphalan (840 mg over 18
months) and had poor count recovery after the trans-
plantation. This patient required frequent use of
growth factors to maintain ANC 500/L and even-
tually developed therapy-related myelodysplasia.
Platelet recovery was rapid for most patients. In 5 of
11 evaluable patients, the platelet count never fell
below 20 000/L. Three patients experienced poor
platelet recovery and required long-term platelet
transfusion support. All had been treated with mel-
phalan before stem cell collection. Two of these 3
patients were described above because they experi-
enced prolonged neutropenia as well, but the third
patient ultimately recovered with platelet count
20 000/L at 9 months post-transplantation with-
out signiﬁcant hemorrhagic sequellae.
Maintenance Therapy
Post-transplantation IFN was given as mainte-
nance therapy in 7 patients. Six patients did not re-
ceive IFN because of thrombocytopenia (3), poor per-
formance status (1), or early death (2). For patients
who received IFN, the therapy was tolerated well,
with all patients receiving it for at least a year. Because
many patients did not receive IFN after transplanta-
tion, the effect of IFN on disease control and survival
was not clear in the present study, but no patient
converted from partial remission to complete remis-
sion during IFN therapy.
Hematologic Response to Therapy
Overall, 11 patients were evaluable for hemato-
logic response to chemotherapy, based on the pres-
ence of serum/urine monoclonal protein or bone
marrow plasma cell clone (Table 1). After pretrans-
plantation chemotherapy, 6 patients achieved either
complete (CHR  3) or partial hematologic remis-
sions (PHR  3). Nine patients were evaluable for
response to TBI, and 2 converted from PHR to CHR
by 100 days post-transplantation. Three patients
maintained the CHR achieved after pretransplanta-
tion chemotherapy. Overall, CHR was achieved in
45% of evaluable patients (5/11) treated on this pro-
tocol.
Outcomes of patients based on achievement of
CHR or PHR were assessed. Of the 5 patients who
achieved CHR, 2 patients were alive and in remission
on days 720 and 266 at last follow-up. Two pa-
tients died with progressive amyloidosis (post-trans-
plantation days781 and577), and 1 patient died of
MDS and pneumonia (day 332) with AL amyloid-
osis in remission. One patient achieved PHR follow-
ing pretransplantation chemotherapy but did not con-
vert to CHR after transplantation. This patient
subsequently died of disease progression on day
1024.
Tissue/Organ Response to Therapy
Using objective response criteria for evaluation of
amyloid-related kidney, liver, and heart dysfunction,
10 patients were evaluable for improvement. Three
patients, all of whom had good-risk disease, were not
evaluable because they did not have objective criteria
for evaluation of amyloid-related dysfunction in these
3 organs. Five patients (50%) had organ function
improvement. Amyloid-related kidney dysfunction
improved (at least 50% decrease in proteinuria as
described previously) in 3 of 5 patients with nephrotic
range proteinuria following chemotherapy, and an-
other patient had kidney improvement after trans-
plantation. Improvement criteria were not met for
amyloid-related liver dysfunction in any patient from
chemotherapy alone, but liver function improved
(50% decrease in alkaline phosphatase) in 2 of 5 pa-
tients who had predominant liver involvement follow-
ing TBI. No improvement in amyloid-related cardiac
dysfunction was seen following chemotherapy or TBI.
Two patients experienced objective improvements in
both kidney and liver function following TBI. Table 1
shows organ responses following chemotherapy or
TBI.
Survival Estimates/Outcomes
Overall survival from enrollment through 100
days post-transplantation for all 13 patients was 85%.
TRM in the ﬁrst 100 days post-transplantation was
15%, including 1 patient who died 1 month after
mobilization because of progressive amyloid cardio-
myopathy. Although the intent of this report was to
describe the safety and feasibility of the transplanta-
tion regimen, outcomes beyond 100 days are also
reported. Kaplan-Meier estimates of overall survival
from enrollment to 1 and 2 years post-transplantation
were 66% and 47%, respectively. Median follow-up
for living patients (4) was 24 months (range, 10 to 32
months). Two of these survivors had good-risk dis-
ease, and 2 had intermediate -risk disease on entry
into the study. Overall, 9 patients expired because of
disease progression (6), MDS/AML (1), arrhythmia
(1), or heart failure 1 month after mobilization (1).
Two patients experienced therapy-related MDS/
AML; both had been previously treated with melpha-
lan. One of these 2 died of pneumonia while AL
amyloidosis was in remission, and the other died be-
cause of progressive amyloidosis with MDS/AML
noted before death.
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Outcomes of patients based on risk group were
assessed. At last follow-up, 2 of the 3 good-risk pa-
tients were alive without disease progression, and 1
died because of progressive amyloidosis. Of the 5
intermediate risk patients, 2 were alive without pro-
gression. One died of disease progression, and 2 died
of TRM. There were 5 poor-risk patients, and all 4
who received transplantation died because of disease
progression. Three of these deaths occurred more
than 1 year post-transplantation. One death occurred
before PBSC collection.
DISCUSSION
Amyloid patients with signiﬁcant organ dysfunc-
tion (3 or more organs) have a 3-fold higher risk of
early death after transplantation than lower risk pa-
tients [11]. By using a novel TBI conditioning regi-
men, we aimed to broaden the applicability of autol-
ogous transplantation for AL amyloidosis. In this
report, we present the results of a comprehensive
treatment approach showing feasibility for both stan-
dard and poor-risk AL amyloidosis patients.
In this trial, conditioning was well tolerated by most
patients, but cardiac toxicity was still signiﬁcant, reﬂect-
ing the experience in high-dose melphalan trials [5].
Conversely, noncardiac organ toxicity was mild and in-
frequent. Signiﬁcant gastrointestinal toxicity (including
mucositis or gastrointestinal bleeding) following TBI
administration was not seen. This contrasts with pub-
lished studies reporting frequent mucositis and gastroin-
testinal bleeding in amyloidosis patients along with a
high parenteral nutrition requirement (21 of 23 pa-
tients in 1 study) following high-dose melphalan or
melphalan/TBI conditioning [5]. Additionally, serious
hepatic, renal, or central nervous system organ toxic-
ity following conditioning did not occur in this TBI-
based trial. Regimen-related pulmonary toxicity
(grade 2 pneumonitis) occurred in 1 patient, and the
patient completely recovered. Brief periods of abso-
lute neutropenia and thrombocytopenia were seen in
most patients; these were associated with a low risk of
serious infectious or hemorrhagic complications.
TRM at 100 days post-transplantation was 15%.
Because patient selection will impact survival in any
nonrandomized study, mortality assessments must
also include an assessment of the patient characteris-
tics. This is particularly true of AL amyloidosis be-
cause the true beneﬁt from autologous transplantation
has been questioned on the basis of selection bias [15].
Small patient numbers in this feasibility trial make it
difﬁcult to compare results with those reported in
much larger studies. However, it should be noted that
Comenzo’s stratiﬁcation guidelines would not recom-
mend standard transplantation for 10 of the 13 patients
included in this trial because they would be expected
to have more complications and inferior outcomes.
Long-term survival data from this study should be
reviewed with caution. While our study focused on
early toxicity, we have provided preliminary data on
long-term follow-up. Overall survival estimates in our
trial of 13 patients were 66% at 1 year and 47% at 2
years post-enrollment. In a larger trial, the Boston
University group reported an overall survival rate of
56% at 1 year post-transplantation [16], and the Mayo
Clinic group reported overall survival at 30 months of
72% [11]. A strong correlation between overall sur-
vival and the number of organs involved by amyloid
has been noted. For patients with more than 2 organs
involved by amyloid, the Mayo Clinic reported overall
survival of less than 20% at 30 months. Similarly,
none of the poor-risk patients in our trial were long-
term responders, with a 2 year survival of 20% (1/5).
For any reduced-toxicity approach to autologous
transplantation to be successful, efﬁcacy must not be
compromised to lower toxicity. The CHR rate for
patients in our trial was 45%. Three of the 5 CHRs
were achieved after chemotherapy alone, with trans-
plantation essentially functioning as consolidation.
Two CHRs were achieved following transplantation
in patients who had PHR after chemotherapy.
Whether or not patients with CHR after chemother-
apy would have performed equally as well if they had
been conditioned with TBI without preceding chemo-
therapy is unknown. The use of pretransplantation
chemotherapy for amyloidosis was recently investi-
gated in a randomized trial (n  100) showing a
survival disadvantage to patients who received pre-
transplantation chemotherapy before high-dose mel-
phalan conditioning (58% vs 70% at 1 year) [17].
However, the trial used only 2 cycles of MP before
transplantation, and the CHR rate from chemother-
apy alone was not reported. The rate of CHR attrib-
utable to TBI alone in our trial was only 2 of 9
patients, but the efﬁcacy of the conditioning regimen
in this feasibility trial is unclear with such a small
number of patients.
In our study, 2 patients developed AML/MDS.
Both patients received extensive melphalan therapy
before transplantation at doses of 400 mg and 840 mg,
respectively. Published experience for AL amyloidosis
patients treated with conventional-dose melphalan
(without transplantation) quoted a 5.4% risk of devel-
oping MDS/AML [1]. The risk of therapy-related
MDS following autologous transplantation for other
diseases ranged from 3% to 24% in 1 review [18] and
was estimated at 8.5% in another study [19]. A recent
case-control study in lymphoma reported that the
relative risk of developing post-autologous transplan-
tation MDS/AML for patients who received pretrans-
plantation alkylator therapy (speciﬁcally mechoreth-
amine and chlorambucil) was up to 16.5 times higher
[20]. Doses of TBI greater than 12 Gy also increased
the risk, but not doses, between 5 and 12 Gy. In our
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study, the risk of developing MDS/AML was high
(15%). Both the total dose of TBI as well as the
elevated dose rate (30 cGy/min) may have contributed
to this. Avoidance of melphalan before PBSC collec-
tion, especially when TBI-based conditioning is used,
should be recommended in future studies for amyloid-
osis. Likewise, assessment of cytogenetics before mo-
bilization would help to delineate the causal factors for
developing MDS from TBI.
In conclusion, single-dose TBI conditioning was fea-
sible for AL amyloidosis patients with modest TRM.
Antiplasma cell efﬁcacy from the comprehensive ap-
proach used here was similar to that from earlier reports,
but much of the beneﬁt was because of the pretransplan-
tation chemotherapy. Currently, the standard condition-
ing regimen for AL amyloidosis is high-dose melphalan.
Modiﬁcations of the melphalan approach will be neces-
sary to allow safe inclusion of poor-risk patients in trans-
plantation protocols, and the alternative approach re-
ported here suggests that it is feasible to do so. Poor-risk
patients tolerated the regimen well, although none were
long-term survivors. This report provides an alternative
framework for future studies in AL amyloidosis, and
consideration should be given to using low-dose, high-
dose-rate TBI in combination with other therapies to
improve response rates and overall survival, especially for
poor-risk patients.
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